Dallas--The two most significant developments in the management of benignprostatic hyperplasia in the past year were the release of the AUA updateof clinical guidelines for the condition and analysis of data from the MedicalTherapy of Prostatic Symptoms (MTOPS) trial, said Claus G. Roehrborn, MD,professor and chairman of the department of urology, University of TexasSouthwestern Medical Center, Dallas.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.